Cargando…

Pretreatment Computed Tomography-Based Machine Learning Models to Predict Outcomes in Hepatocellular Carcinoma Patients who Received Combined Treatment of Trans-Arterial Chemoembolization and Tyrosine Kinase Inhibitor

Aim: Trans-arterial chemoembolization (TACE) in combination with tyrosine kinase inhibitor (TKI) has been evidenced to improve outcomes in a portion of patients with hepatocellular carcinoma (HCC). Developing biomarkers to identify patients who might benefit from the combined treatment is needed. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Qianqian, Zhu, Peng, Li, Changde, Yan, Meijun, Liu, Song, Zheng, Chuansheng, Xia, Xiangwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168370/
https://www.ncbi.nlm.nih.gov/pubmed/35677305
http://dx.doi.org/10.3389/fbioe.2022.872044
_version_ 1784720993617444864
author Ren, Qianqian
Zhu, Peng
Li, Changde
Yan, Meijun
Liu, Song
Zheng, Chuansheng
Xia, Xiangwen
author_facet Ren, Qianqian
Zhu, Peng
Li, Changde
Yan, Meijun
Liu, Song
Zheng, Chuansheng
Xia, Xiangwen
author_sort Ren, Qianqian
collection PubMed
description Aim: Trans-arterial chemoembolization (TACE) in combination with tyrosine kinase inhibitor (TKI) has been evidenced to improve outcomes in a portion of patients with hepatocellular carcinoma (HCC). Developing biomarkers to identify patients who might benefit from the combined treatment is needed. This study aims to investigate the efficacy of radiomics/deep learning features-based models in predicting short-term disease control and overall survival (OS) in HCC patients who received the combined treatment. Materials and Methods: A total of 103 HCC patients who received the combined treatment from Sep. 2015 to Dec. 2019 were enrolled in the study. We exacted radiomics features and deep learning features of six pre-trained convolutional neural networks (CNNs) from pretreatment computed tomography (CT) images. The robustness of features was evaluated, and those with excellent stability were used to construct predictive models by combining each of the seven feature exactors, 13 feature selection methods and 12 classifiers. The models were evaluated for predicting short-term disease by using the area under the receiver operating characteristics curve (AUC) and relative standard deviation (RSD). The optimal models were further analyzed for predictive performance on overall survival. Results: A total of the 1,092 models (156 with radiomics features and 936 with deep learning features) were constructed. Radiomics_GINI_Nearest Neighbors (RGNN) and Resnet50_MIM_Nearest Neighbors (RMNN) were identified as optimal models, with the AUC of 0.87 and 0.94, accuracy of 0.89 and 0.92, sensitivity of 0.88 and 0.97, specificity of 0.90 and 0.90, precision of 0.87 and 0.83, F1 score of 0.89 and 0.92, and RSD of 1.30 and 0.26, respectively. Kaplan-Meier survival analysis showed that RGNN and RMNN were associated with better OS (p = 0.006 for RGNN and p = 0.033 for RMNN). Conclusion: Pretreatment CT-based radiomics/deep learning models could non-invasively and efficiently predict outcomes in HCC patients who received combined therapy of TACE and TKI.
format Online
Article
Text
id pubmed-9168370
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91683702022-06-07 Pretreatment Computed Tomography-Based Machine Learning Models to Predict Outcomes in Hepatocellular Carcinoma Patients who Received Combined Treatment of Trans-Arterial Chemoembolization and Tyrosine Kinase Inhibitor Ren, Qianqian Zhu, Peng Li, Changde Yan, Meijun Liu, Song Zheng, Chuansheng Xia, Xiangwen Front Bioeng Biotechnol Bioengineering and Biotechnology Aim: Trans-arterial chemoembolization (TACE) in combination with tyrosine kinase inhibitor (TKI) has been evidenced to improve outcomes in a portion of patients with hepatocellular carcinoma (HCC). Developing biomarkers to identify patients who might benefit from the combined treatment is needed. This study aims to investigate the efficacy of radiomics/deep learning features-based models in predicting short-term disease control and overall survival (OS) in HCC patients who received the combined treatment. Materials and Methods: A total of 103 HCC patients who received the combined treatment from Sep. 2015 to Dec. 2019 were enrolled in the study. We exacted radiomics features and deep learning features of six pre-trained convolutional neural networks (CNNs) from pretreatment computed tomography (CT) images. The robustness of features was evaluated, and those with excellent stability were used to construct predictive models by combining each of the seven feature exactors, 13 feature selection methods and 12 classifiers. The models were evaluated for predicting short-term disease by using the area under the receiver operating characteristics curve (AUC) and relative standard deviation (RSD). The optimal models were further analyzed for predictive performance on overall survival. Results: A total of the 1,092 models (156 with radiomics features and 936 with deep learning features) were constructed. Radiomics_GINI_Nearest Neighbors (RGNN) and Resnet50_MIM_Nearest Neighbors (RMNN) were identified as optimal models, with the AUC of 0.87 and 0.94, accuracy of 0.89 and 0.92, sensitivity of 0.88 and 0.97, specificity of 0.90 and 0.90, precision of 0.87 and 0.83, F1 score of 0.89 and 0.92, and RSD of 1.30 and 0.26, respectively. Kaplan-Meier survival analysis showed that RGNN and RMNN were associated with better OS (p = 0.006 for RGNN and p = 0.033 for RMNN). Conclusion: Pretreatment CT-based radiomics/deep learning models could non-invasively and efficiently predict outcomes in HCC patients who received combined therapy of TACE and TKI. Frontiers Media S.A. 2022-05-23 /pmc/articles/PMC9168370/ /pubmed/35677305 http://dx.doi.org/10.3389/fbioe.2022.872044 Text en Copyright © 2022 Ren, Zhu, Li, Yan, Liu, Zheng and Xia. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Bioengineering and Biotechnology
Ren, Qianqian
Zhu, Peng
Li, Changde
Yan, Meijun
Liu, Song
Zheng, Chuansheng
Xia, Xiangwen
Pretreatment Computed Tomography-Based Machine Learning Models to Predict Outcomes in Hepatocellular Carcinoma Patients who Received Combined Treatment of Trans-Arterial Chemoembolization and Tyrosine Kinase Inhibitor
title Pretreatment Computed Tomography-Based Machine Learning Models to Predict Outcomes in Hepatocellular Carcinoma Patients who Received Combined Treatment of Trans-Arterial Chemoembolization and Tyrosine Kinase Inhibitor
title_full Pretreatment Computed Tomography-Based Machine Learning Models to Predict Outcomes in Hepatocellular Carcinoma Patients who Received Combined Treatment of Trans-Arterial Chemoembolization and Tyrosine Kinase Inhibitor
title_fullStr Pretreatment Computed Tomography-Based Machine Learning Models to Predict Outcomes in Hepatocellular Carcinoma Patients who Received Combined Treatment of Trans-Arterial Chemoembolization and Tyrosine Kinase Inhibitor
title_full_unstemmed Pretreatment Computed Tomography-Based Machine Learning Models to Predict Outcomes in Hepatocellular Carcinoma Patients who Received Combined Treatment of Trans-Arterial Chemoembolization and Tyrosine Kinase Inhibitor
title_short Pretreatment Computed Tomography-Based Machine Learning Models to Predict Outcomes in Hepatocellular Carcinoma Patients who Received Combined Treatment of Trans-Arterial Chemoembolization and Tyrosine Kinase Inhibitor
title_sort pretreatment computed tomography-based machine learning models to predict outcomes in hepatocellular carcinoma patients who received combined treatment of trans-arterial chemoembolization and tyrosine kinase inhibitor
topic Bioengineering and Biotechnology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168370/
https://www.ncbi.nlm.nih.gov/pubmed/35677305
http://dx.doi.org/10.3389/fbioe.2022.872044
work_keys_str_mv AT renqianqian pretreatmentcomputedtomographybasedmachinelearningmodelstopredictoutcomesinhepatocellularcarcinomapatientswhoreceivedcombinedtreatmentoftransarterialchemoembolizationandtyrosinekinaseinhibitor
AT zhupeng pretreatmentcomputedtomographybasedmachinelearningmodelstopredictoutcomesinhepatocellularcarcinomapatientswhoreceivedcombinedtreatmentoftransarterialchemoembolizationandtyrosinekinaseinhibitor
AT lichangde pretreatmentcomputedtomographybasedmachinelearningmodelstopredictoutcomesinhepatocellularcarcinomapatientswhoreceivedcombinedtreatmentoftransarterialchemoembolizationandtyrosinekinaseinhibitor
AT yanmeijun pretreatmentcomputedtomographybasedmachinelearningmodelstopredictoutcomesinhepatocellularcarcinomapatientswhoreceivedcombinedtreatmentoftransarterialchemoembolizationandtyrosinekinaseinhibitor
AT liusong pretreatmentcomputedtomographybasedmachinelearningmodelstopredictoutcomesinhepatocellularcarcinomapatientswhoreceivedcombinedtreatmentoftransarterialchemoembolizationandtyrosinekinaseinhibitor
AT zhengchuansheng pretreatmentcomputedtomographybasedmachinelearningmodelstopredictoutcomesinhepatocellularcarcinomapatientswhoreceivedcombinedtreatmentoftransarterialchemoembolizationandtyrosinekinaseinhibitor
AT xiaxiangwen pretreatmentcomputedtomographybasedmachinelearningmodelstopredictoutcomesinhepatocellularcarcinomapatientswhoreceivedcombinedtreatmentoftransarterialchemoembolizationandtyrosinekinaseinhibitor